Dr Reddy's launches generic Lamotrigine tablets in US
Lamictal is indicated as adjunctive therapy for the certain type of seizures and for the maintenance treatment of bipolar disorder.
By PTI | Updated:
NEW DELHI: Pharmaceutical major Dr Reddy's Laboratories today said it has launched generic Lamotrigine orally disintegrating tablets used for treatment of certain types of seizures in epileptic patients in the US market.
The company's tablets are in the strengths of 25 mg, 50 mg, 100 mg and 200 mg, Dr Reddy's Laboratories said in a filing to BSE.
The company's product is generic version of GSK Group of companies' Lamictal tablets, it added.
"The Lamictal ODT brand and generic had US sales of approximately $65.5 million MAT for the most recent twelve months ending July 2016 according to IMS Health," Dr Reddy's Laboratories said.
Lamictal is indicated as adjunctive therapy for the certain type of seizures and for the maintenance treatment of bipolar disorder.
The company's tablets are in the strengths of 25 mg, 50 mg, 100 mg and 200 mg, Dr Reddy's Laboratories said in a filing to BSE.
The company's product is generic version of GSK Group of companies' Lamictal tablets, it added.
"The Lamictal ODT brand and generic had US sales of approximately $65.5 million MAT for the most recent twelve months ending July 2016 according to IMS Health," Dr Reddy's Laboratories said.
Lamictal is indicated as adjunctive therapy for the certain type of seizures and for the maintenance treatment of bipolar disorder.
Start a SIP with as low as ₹500 with ET Money App!
Download
The Economic Times News App for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.
The Economic Times News App for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.
ADVERTISEMENT
